Drug intelligence / Profile preview

NI03

Development stage: Preclinical
Lead developer: Amprologix
Modality: Peptides

Overview

NI03 is an antimicrobial peptide (AMP) being developed by Amprologix for the treatment of infections caused by the Gram-negative bacterium *Acinetobacter baumannii*. As a bactericidal biologic, NI03 is part of a platform of peptide-based antibiotics designed to combat multi-drug resistant (MDR) pathogens. The drug is currently in the preclinical discovery stage, specifically undergoing in vitro screening to establish its efficacy profile against WHO priority pathogens.

Beyond the preview

Go deeper on NI03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NI03.

Explore the full profile